Yi Chang
Director/Board Member chez NONGFU SPRING CO., LTD.
Profil
Yi Chang is currently an Independent Non-Executive Director at Nongfu Spring Co., Ltd., YishengBio Co., Ltd., Sipai Health Technology Co., Ltd., and Cowealth Medical China Co., Ltd.
He is also a Member of the China Institute of Internal Audit and the Asian Development Bank China.
In addition, he is a Professor at Shanghai Advanced Institute of Finance and the Managing Partner at Grant Thornton LLP (China).
Previously, Dr. Chang served as an Independent Director at YS Biopharma Co. Ltd.
and Chief Operating Officer at Marcum Asia CPAs LLP.
He was also a Professor at National Taiwan University from 2016 to 2018 and a Partner at Ernst & Young (China) from 2007 to 2016.
Additionally, he was a Member of the Texas State Board of Public Accountancy.
Dr. Chang's education includes a graduate degree from the University of Missouri in 1983, a doctorate degree from Texas Tech University in 1987, and an undergraduate degree from National Taiwan University in 1980.
Postes actifs de Yi Chang
Sociétés | Poste | Début |
---|---|---|
NONGFU SPRING CO., LTD. | Director/Board Member | 06/03/2020 |
SIPAI HEALTH TECHNOLOGY CO., LTD. | Director/Board Member | 30/07/2021 |
COWEALTH MEDICAL CHINA CO.,LTD. | Director/Board Member | 22/03/2019 |
China Institute of Internal Audit | Corporate Officer/Principal | - |
Asian Development Bank China | Corporate Officer/Principal | - |
Shanghai Advanced Institute of Finance | Corporate Officer/Principal | 01/07/2018 |
Grant Thornton LLP (China) | Corporate Officer/Principal | - |
YishengBio Co., Ltd.
YishengBio Co., Ltd. BiotechnologyHealth Technology Yishengbio Co., Ltd. is an investment holding company that engages in the research and development, manufacture, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on the PIKA immunomodulation technology platform and production, sale of YSJA rabies vaccine. Its geographical segment include Mainland China, and other countries. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in China. | Director/Board Member | 19/01/2021 |
Anciens postes connus de Yi Chang
Sociétés | Poste | Fin |
---|---|---|
YS BIOPHARMA CO., LTD. | Director/Board Member | 09/12/2023 |
░░░░░░░░ ░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░ ░░░░░ ░░ ░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░░░░ ░░░░ ░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Formation de Yi Chang
University of Missouri | Graduate Degree |
Texas Tech University | Doctorate Degree |
National Taiwan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
NONGFU SPRING CO., LTD. | Consumer Non-Durables |
SIPAI HEALTH TECHNOLOGY CO., LTD. | Retail Trade |
COWEALTH MEDICAL CHINA CO.,LTD. | Health Technology |
YS BIOPHARMA CO., LTD. | Health Technology |
Entreprise privées | 7 |
---|---|
Texas State Board of Public Accountancy | |
China Institute of Internal Audit | |
Ernst & Young (China) | |
Marcum Asia CPAs LLP
Marcum Asia CPAs LLP Miscellaneous Commercial ServicesCommercial Services Part of Marcum Wealth LLC, Marcum Asia CPAs LLP provides public accounting services. The private company is based in Beijing, China. The CEO of the Chinese company is Enze Liang. | Commercial Services |
Asian Development Bank China | Government |
Grant Thornton LLP (China) | |
YishengBio Co., Ltd.
YishengBio Co., Ltd. BiotechnologyHealth Technology Yishengbio Co., Ltd. is an investment holding company that engages in the research and development, manufacture, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on the PIKA immunomodulation technology platform and production, sale of YSJA rabies vaccine. Its geographical segment include Mainland China, and other countries. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in China. | Health Technology |